Cytokinetics EVP Sells $293K in Shares

Fady Ibraham Malik reduces stake by 2.84% through pre-arranged trading plan

Apr. 8, 2026 at 10:26pm

Got story updates? Submit your updates here. ›

An extreme close-up of the internal components and circuitry of a stock trading terminal, conveying the technical complexity and institutional nature of modern finance.An insider's view of the complex machinery powering the financial markets, hinting at the intricate transactions that drive stock prices.South San Francisco Today

Cytokinetics, Incorporated (NASDAQ:CYTK) Executive Vice President Fady Ibraham Malik sold 4,500 shares of the company's stock on April 7th, 2026 for a total transaction value of $292,995. Following the sale, Malik directly owns 153,902 shares in the biopharmaceutical company, valued at approximately $10 million.

Why it matters

Insider sales can provide insight into an executive's confidence in their company's outlook and future performance. Malik's sale, executed through a pre-arranged trading plan, represents a 2.84% reduction in his personal stake in Cytokinetics.

The details

The shares were sold at an average price of $65.11 per share. Malik has made several other recent sales of Cytokinetics stock, including 12,033 shares on March 17th and 2,907 shares on March 9th. The transactions were disclosed in a filing with the Securities and Exchange Commission.

  • The shares were sold on April 7th, 2026.
  • Malik also sold 12,033 shares on March 17th, 2026.
  • Malik sold 2,907 shares on March 9th, 2026.

The players

Fady Ibraham Malik

Executive Vice President of Cytokinetics, Incorporated.

Cytokinetics, Incorporated

A late-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that modulate muscle function.

Got photos? Submit your photos here. ›

The takeaway

Insider transactions can provide valuable signals about a company's prospects, though investors should consider them alongside other fundamental and technical analysis. Malik's recent sales suggest he may be taking some chips off the table, but Cytokinetics remains a closely watched biotech stock with several promising drug candidates in development.